Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

NUT midline carcinoma

Nature Reviews Cancer volume 14, pages 149–150 (2014)Cite this article

Subjects

Abstract

NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease. Will the new bromodomain and extra terminal (BET) inhibitors prove to be one such treatment for this rare and enigmatic cancer?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: A model of how BRD4–NUT might block differentiation.

References

  1. French, C. A. et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27, 2237–2242 (2008).

    Article  CAS  Google Scholar 

  2. Bauer, D. et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin. Cancer Res. 18, 5773–5779 (2012).

    Article  Google Scholar 

  3. Haack, H. et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am. J. Surg. Pathol. 33, 984–991 (2009).

    Article  Google Scholar 

  4. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

    Article  CAS  Google Scholar 

  5. Reynoird, N. et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29, 2943–2952 (2010).

    Article  CAS  Google Scholar 

  6. Grayson, A. R. et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene http://dx.doi.org/10.1038/onc.2013.126 (2013).

  7. Schwartz, B. E. et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 71, 2686–2696 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Brigham and Womens Hospital, Harvard Medical School, 75 Francis Street, Boston, 02115, Massachusetts, USA

    Christopher French

Authors
  1. Christopher French
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher French.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

French, C. NUT midline carcinoma. Nat Rev Cancer 14, 149–150 (2014). https://doi.org/10.1038/nrc3659

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrc3659

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer